You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Biomimetic Wound Healing Devices to Close Diabetic Wounds
SBC: PROTEIN GENOMICS INC. Topic: NIDDKThe long term objective of this project is the synthesis and assembly of wound healing devices that mimic as closely as possible the biochemical and mechanical characteristics of healthy human skin The proposed research would focus on the synthesis of membranes containing electrospun human recombinant tropoelastin and collagen mixtures The ratios of the two molecules and the spinning condition ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Scaffold to Promote Skin Regeneration
SBC: FirstString Research, Inc Topic: NIAMSPROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIPolo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Regulators of NaV Channels Novel Anti Allodynic Drug Candidates
SBC: Regulonix Topic: 102PROJECT SUMMARY Chemotherapy induced peripheral neuropathy CIPN is a common prevalence and potentially dose limiting side effect of many cancer chemotherapy drug treatment regimens Clinically CIPN presents with pain that is burning shooting or electric shock like The increase in prevalence of cancer coupled with an increase in the cancer survival rates due to chemotherapy regimens ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Application of PPODA QT for embolization of aneurysms
SBC: ANEUVAS TECHNOLOGIES INC Topic: 101A cerebral aneurysm is an abnormal enlargement or pouch that forms from a weakened vessel segment in the brain Often going unnoticed and untreated an aneurysm can cause a sudden and catastrophic hemorrhage or stroke Approximately of patients die from an aneurysm rupture even before receiving medical attention and of patients die despite medical treatment Patients that survive typical ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers.
SBC: PROMUTECH PHARMACEUTICALS, INC. Topic: 102DESCRIPTION provided by applicant Pathological activating mutations in the FLT kinase represent the most common genetic alteration in patients with acute myeloid leukemia AML occurring in approximately one third of cases Recently we performed translational studies that identified drug resistant kinase domain mutations in FLT ITD at the time of relapse in AML patients treated with the FLT ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Synactix Pharmaceuticals I-Corps Application
SBC: SYNACTIX PHARMACEUTICALS, INC. Topic: 102DESCRIPTION provided by applicant Polypharmacology represents a new and attractive approach to treat malignances as lasting and robust efficacy could be obtained through the inhibition of multiple survival pathways with one therapeutic agent In line with this method we have designed a RET rearranged during transfection VEGFR vascular endothelial growth factor receptor small molecule ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Extraction and Characterization of a Safer, Cost-effective Anti-inflammatory
SBC: Botanisol LLC Topic: RDESCRIPTION provided by applicant Inflammatory disease states are leading causes of death and disability and a major cost to healthcare in the United States There is an epidemic of death and hospitalizations due to adverse effects from NSAIDs TAI LCx Turmeric Anti Inflammatory Lipophilic Component X is a novel anti inflammatory discovered in previously unrecognized pharmacologically activ ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Stroke Treatment by Chemically-induced Hypothermia
SBC: JT Pharmaceuticals, Inc. Topic: 101DESCRIPTION provided by applicant Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder novel strategies that target multiple cell types and different mechanisms are needed to achieve therapeut ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Reduced gluten cereal grains
SBC: Arcadia Biosciences, Inc. Topic: 300DESCRIPTION provided by applicant Celiac disease CD is the most common food sensitive enteropathy known affecting approximately of the population and its incidence appears to be on the rise In addition non celiac gluten sensitivity GS has recently been revealed to be a distinct condition that affects a growing number of individuals Both of these conditions are triggered by gluten a ...
STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health